Oral Versus Intravenous Iron for Treatment of Iron Deficiency Anaemia in Pregnancy: A Randomized Controlled Trial

2018 ◽  
Vol 9 (6) ◽  
pp. 1 ◽  
Author(s):  
Monika Dalal ◽  
Ritu Goyal ◽  
Smiti Nanda ◽  
Pushpa Dahiya ◽  
Krishna Dahiya ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Iron Deficiency ◽  
Iron Deficiency Anaemia ◽  
Controlled Trial ◽  
Intravenous Iron ◽  
Deficiency Anaemia ◽  
Randomized Controlled ◽  
Anaemia In Pregnancy ◽  
In Pregnancy

scholarly journals RAPIDIRON: Reducing Anaemia in Pregnancy in India—a 3-arm, randomized-controlled trial comparing the effectiveness of oral iron with single-dose intravenous iron in the treatment of iron deficiency anaemia in pregnant women and reducing low birth weight deliveries

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Richard J. Derman ◽  
Shivaprasad S. Goudar ◽  
Simal Thind ◽  
Sudhir Bhandari ◽  
Zubair Aghai ◽  
...  
Keyword(s):  
Single Dose ◽  
Iron Deficiency ◽  
Iron Deficiency Anaemia ◽  
Controlled Trial ◽  
Intravenous Iron ◽  
Oral Iron ◽  
Reproductive Age ◽  
Deficiency Anaemia ◽  
Randomized Controlled ◽  
In Pregnancy

Abstract Background Anaemia is a worldwide problem and iron deficiency is the most common cause. In pregnancy, anaemia increases the risk of adverse maternal, foetal and neonatal outcomes. India’s anaemia rate is among the highest in the world with India’s National Family Health Survey indicating over 50% of pregnant women were affected by anaemia. India’s Anaemia Mukt Bharat-Intensified National Iron Plus Initiative aims to reduce the prevalence of anaemia among reproductive-age women, adolescents and children by 3% per year and facilitate the achievement of a Global World Health Assembly 2025 objective to achieve a 50% reduction of anaemia among women of reproductive age. However, preliminary results of the NFHS-5 survey completed in 2020 indicate that anaemia rates are increasing in some states and these targets are unlikely to be achieved. With oral iron being the first-line treatment for iron deficiency anaemia (IDA) in pregnancy, these results are likely to be impacted by the side effects, poor adherence to tablet ingestion and low therapeutic impact of oral iron. These reports suggest a new approach to treating IDA, specifically the importance of single-dose intravenous iron infusions, may be the key to India effectively reaching its targets for anaemia reduction. Methods This 3-arm, randomized controlled trial is powered to report two primary outcomes. The first is to assess whether a single dose of two different intravenous formulations administered early in the second trimester of pregnancy to women with moderate IDA will result in a higher percentage of participants achieving a normal for pregnancy Hb concentration at 30–34 weeks’ gestation or just prior to delivery when compared to participants taking standard doses of oral iron. The second is a clinical outcome of low birth weight (LBW) (< 2500 g), with a hypothesis that the risk of LBW delivery will be lower in the intravenous iron arms when compared to the oral iron arm. Discussion The RAPIDIRON trial will provide evidence to determine if a single-dose intravenous iron infusion is more effective and economically feasible in reducing IDA in pregnancy than the current standard of care. Trial registration Clinical Trials Registry – India CTRI/2020/09/027730. Registered on 10 September 2020, http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=46801&EncHid=&userName=anemia%20in%20pregnancy

scholarly journals RAPIDIRON: Reducing Anaemia in Pregnancy in India A 3-Arm, Randomized-Controlled Trial Comparing The Effectiveness of Oral Iron With Single-Dose Intravenous Iron In The Treatment of Iron Deficiency Anaemia In Pregnant Women And Reducing Low Birth Weight Deliveries.

2021 ◽  
Author(s):  
Richard Derman ◽  
Shivaprasad Goudar ◽  
Simal Thind ◽  
Sudhir Bhandari ◽  
Zubair Aghai ◽  
...  
Keyword(s):  
Single Dose ◽  
Iron Deficiency ◽  
Iron Deficiency Anaemia ◽  
Controlled Trial ◽  
Intravenous Iron ◽  
Oral Iron ◽  
Reproductive Age ◽  
Deficiency Anaemia ◽  
Randomized Controlled ◽  
In Pregnancy

Abstract Background: Anaemia is a worldwide problem and iron deficiency is the most common cause. In pregnancy, anaemia increases the risk of adverse maternal, foetal and neonatal outcomes.India’s anaemia rate is among the highest in the world with India’s National Family Health Survey indicating over 50% of pregnant women were affected by anaemia. India’s Anaemia Mukt Bharat-Intensified National Iron Plus Initiative aims to reduce the prevalence of anaemia among reproductive-age women, adolescents and children by 3% per year and facilitate the achievement of a Global World Health Assembly 2025 objective to achieve a 50% reduction of anaemia among women of reproductive age. However, preliminary results of the NFHS-5 survey completed in 2020 indicate that anaemia rates are increasing in some states and these targets are unlikely to be achieved. With oral iron being the first-line treatment for iron deficiency anaemia (IDA) in pregnancy, these results are likely to be impacted by the side effects, poor adherence to tablet ingestion and low therapeutic impact of oral iron. These reports suggest a new approach to treating IDA, specifically the importance of single-dose intravenous iron infusions, may be the key to India effectively reaching its targets for anaemia reduction. Methods: This 3-arm, randomized controlled trial is powered to report two primary outcomes. The first is to assess whether a single dose of two different intravenous formulations administered early in the second trimester of pregnancy to women with moderate IDA will result in a higher percentage of participants achieving a normal for pregnancy Hb concentration at 30-34 weeks’ gestation or just prior to delivery when compared to participants taking standard doses of oral iron. The second is a clinical outcome of low birth weight (LBW) (< 2500 grams), with a hypothesis that the risk of LBW delivery will be lower in the intravenous iron arms when compared to the oral iron arm. Discussion: The RAPIDIRON trial will provide evidence to determine if a single-dose intravenous iron infusion is more effective and economically feasible in reducing IDA in pregnancy than the current standard of care.Trial registration: Clinical Trials Registry – India: CTRI/2020/09/027730. Registered 10 September 2020, http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=46801&EncHid=&userName=anemia%20in%20pregnancy

Hepcidin-Guided Screen-and-Treat Interventions Against Iron Deficiency Anaemia in Pregnancy: A Randomised Controlled Trial in Gambian Women

2019 ◽  
Author(s):  
Amat Bah ◽  
Abdul Khalie Muhammad ◽  
Rita Wegmuller ◽  
Hans Verhoef ◽  
Morgan M. Goheen ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Iron Deficiency ◽  
Iron Deficiency Anaemia ◽  
Controlled Trial ◽  
Deficiency Anaemia ◽  
Anaemia In Pregnancy ◽  
Randomised Controlled ◽  
In Pregnancy

scholarly journals Evaluation of safety and efficacy of intravenous iron sucrose therapy for moderate anaemia in antenatal women

2019 ◽  
Vol 8 (10) ◽  
pp. 2258
Author(s):  
K. P. Poojitha ◽  
B. S. B. Mallika ◽  
K. V. Siva Prasad
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anaemia ◽  
Haemoglobin Concentration ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
Efficacy And Safety ◽  
Deficiency Anaemia ◽  
Anaemia In Pregnancy ◽  
Moderate Anaemia ◽  
In Pregnancy

Background: Prevalence of iron deficiency anaemia is high in developing countries like India. Treatment of iron deficiency anaemia in pregnancy is very important to bring down maternal mortality rate as blood loss during delivery can lead to death of the patient. The aim and objective of our study is to evaluate the efficacy and safety of intravenous iron sucrose infusions in antenatal women admitted in hospital suffering from moderate iron deficiency anaemia. Special emphasis was given to observe adverse drug effects.Methods: This was a prospective observational study conducted in Obstetrics and Gynaecology department, Government General Hospital, Rangaraya Medical College, Kakinada, Andhra Pradesh. Study period was two months and study population included antenatal women with gestational age less than 37 weeks with moderate iron deficiency anaemia. Peripheral smear was examined for microcytic hypochromic anaemia and they were treated with intravenous infusion of iron sucrose. Haemoglobin levels were checked before and 5 weeks after iron infusions. Monitoring was done for adverse reactions.Results: Out of 322 admissions, 95% were found to be anaemic. 72 patients were suffering from moderate anaemia from which 25 have been included and treated with intravenous iron sucrose infusions. They were observed for efficacy and safety parameters. Two minor adverse events were reported (fever with chills and angioedema of lips) and they were excluded from study. Mean haemoglobin concentration was found to be raised from 7.08±0.73 (SD) to 11.33±0.48 (SD) within 5 weeks for 23 patients.Conclusions: Iron sucrose infusion is safe and effective for anaemia in pregnancy.

scholarly journals Anaemia in pregnancy: prevalence and treatment response to various modalities: a prospective study

2020 ◽  
Vol 9 (9) ◽  
pp. 3784
Author(s):  
G. D. Maiti ◽  
Shilpa Gupta ◽  
Jaskanwar Singh
Keyword(s):  
Iron Deficiency ◽  
Pregnant Women ◽  
Iron Deficiency Anaemia ◽  
Intravenous Iron ◽  
Iron Therapy ◽  
Deficiency Anaemia ◽  
Thalassemia Trait ◽  
Anaemia In Pregnancy ◽  
Intravenous Iron Therapy ◽  
In Pregnancy

Background: Anaemia seen in pregnancy are largely preventable and easily treatable if detected in time, despite this, anaemia still continues to be a common cause of maternal and perinatal morbidity and mortality in India.Methods: A prospective observational study of 200 pregnant women with anaemia was carried out from Jun 2017 to December 2018 at a Tertiary care hospital with pan India population. Patients underwent clinical examination and laboratory tests to find out the severity and type of anaemia and were treated accordingly. Iron deficiency anaemia was treated with oral or intravenous iron therapy depending upon the hemoglobin concentration. Patients were followed up after 28 days of treatment and hemoglobin estimation was done to monitor the treatment response.Results: A total 36.49% pregnant women had hemoglobin less than 10 gm%. 151 out of 200 women had serum ferritin <12 ng/ml which indicates that iron deficiency anaemia is the commonest type of anaemia in pregnancy. Overall, out of 200 patients 5.5% patients were found to have hemoglobinopathies (β thalassemia trait). After 28 days of treatment mean increase in hemoglobin was 2.40 gm% and 4.24 gm% in patients receiving oral and intravenous iron therapy respectively.Conclusions: A total 36.49% pregnant women were found to have anaemia during pregnancy and iron deficiency anaemia is the commonest type of anaemia. Therefore, there is still a need for dietary counselling and health education in the community. 5.5% patients were found to have beta thalassemia trait which was detected only after conducting hemoglobin electrophoresis. Both oral and intravenous iron therapy are effective in treatment of iron deficiency anaemia but intravenous iron therapy results in a more rapid resolution of anaemia.

scholarly journals Effects of Vitamin A Supplementation on Iron Status Indices and Iron Deficiency Anaemia: A Randomized Controlled Trial

Nutrients ◽  
2013 ◽  
Vol 6 (1) ◽  
pp. 190-206 ◽  
Author(s):  
Hesham Al-Mekhlafi ◽  
Ebtesam Al-Zabedi ◽  
Mohamed Al-Maktari ◽  
Wahib Atroosh ◽  
Ahmed Al-Delaimy ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Iron Deficiency ◽  
Vitamin A ◽  
Iron Deficiency Anaemia ◽  
Iron Status ◽  
Controlled Trial ◽  
Vitamin A Supplementation ◽  
Deficiency Anaemia ◽  
Randomized Controlled
Sign in / Sign up

Export Citation Format

Share Document